Xilio Therapeutics, Inc.XLOEarnings & Financial Report
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
Revenue
$2.9M
Gross Profit
N/A
Operating Profit
$-13.9M
Net Profit
$-13.3M
Gross Margin
N/A
Operating Margin
-472.7%
Net Margin
-452.7%
YoY Growth
N/A
EPS
$-0.18
Xilio Therapeutics, Inc. Q1 FY2025 Financial Summary
Xilio Therapeutics, Inc. reported revenue of $2.9M for Q1 FY2025, with a net profit of $-13.3M (up 22.9% YoY) (-452.7% margin).
Key Financial Metrics
| Total Revenue | $2.9M |
|---|---|
| Net Profit | $-13.3M |
| Gross Margin | N/A |
| Operating Margin | -472.7% |
| Report Period | Q1 FY2025 |
Xilio Therapeutics, Inc. Annual Revenue by Year
Xilio Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $43.8M).
| Year | Annual Revenue |
|---|---|
| 2025 | $43.8M |
Xilio Therapeutics, Inc. Quarterly Revenue & Net Profit History
Xilio Therapeutics, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.7M | — | $10.4M | 75.7% |
| Q3 FY2025 | $19.1M | +742.5% | $-16.3M | -85.4% |
| Q2 FY2025 | $8.1M | +243.0% | $-15.8M | -196.0% |
| Q1 FY2025 | $2.9M | — | $-13.3M | -452.7% |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Revenue | $2.9M | $8.1M | $19.1M | $13.7M |
| YoY Growth | N/A | 243.0% | 742.5% | N/A |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Assets | $103.7M | $133.8M | $133.7M | $154.7M |
| Liabilities | $93.0M | $126.7M | $141.8M | $119.4M |
| Equity | $10.7M | $7.1M | $-8.1M | $35.3M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $29.0M | $-14.5M | $-17.5M | $-2.0M |